Drug intelligence / Profile preview

LT-0004

Development stage: Preclinical
Lead developer: LTT Bio-Pharma
Modality: Liposomes → Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems

Overview

LT-0004 is a preclinical-stage drug delivery system (DDS) developed by LTT Bio-Pharma that utilizes liposome technology. It is designed as a versatile platform capable of encapsulating a wide range of therapeutic agents to enhance their delivery, stability, and efficacy. By employing lipid-based vesicles, LT-0004 aims to optimize the pharmacokinetic properties of drugs, potentially reducing systemic toxicity and improving targeted delivery to specific tissues. As a platform technology, it is intended for application across various therapeutic areas rather than being limited to a single disease indication.

Other names: Liposome DDSDrug delivery system (DDS)

Beyond the preview

Go deeper on LT-0004.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LT-0004.

Explore the full profile